Qingsheng Li, Ph.D.

Education:

B.A., Medicine, Wannan Medical College, People’s Republic of China; 1986
M.D., Pediatrics, Sun Yat-Sen Medical University, People’s Republic of China; 1991
Ph.D., Medicine, Shanghai Second Medical University, People’s Republic of China; 1997
Postdoctoral Fellowship, Tumor Immunology, Mount Sinai School of Medicine, New York USA; 2000-2003

Curriculum Vitae 

Current Positions: 

Assistant Professor, Department of Microbiology & Immunology, University of Louisville
Member, James Graham Brown Cancer Center, University of Louisville

Contact Information: 

Department of Microbiology & Immunology
Clinical & Translational Research Building, Room 652A
505 South Hancock Street
University of Louisville
Louisville, KY, 40202, USA
Phone: 502-852-4005
Email: qingsheng.li@louisville.edu

Research Description: 

We study the role of dysfunctional T-cell immunity in lung carcinogenesis and resistance to immune therapy.  Currently, our research combines the use of genetically engineered mouse models (murine Kras lung tumor model) and human tumor samples with specific focus on the analysis of tumor-infiltrating T-cells that influence the responsiveness of tumors to immune checkpoint blockade therapy.  A second project focuses on the role of dietary fiber in the development and progression of lung cancer.

 Literature Cited: 

  1. Mandal RK, Denny JE, Waide ML, Li Q, Bhutiani N, Anderson CD, Baby BV, Jala VR, Egilmez NK, Schmidt NW.  Temporospatial shifts within commercial laboratory mouse gut microbiota impact experimental reproducibility.  BMC Biology 2020;18(1):83.
  2. Gu T, Li Q, Egilmez NK.  IFNβ-producing CX3CR1+ macrophages promote T-regulatory cell expansion and tumor growth in the APCmin/+/Bacteroides fragilis colon cancer model.  OncoImmunology 2019;8(12):e1665975.
  3. Bhutiani N, Li Q, Anderson CD, Gallagher HC, De Jesus M, Singh R, Jala VR, Fraig M, Gu T, Egilmez NK.  Enhanced gut barrier integrity sensitizes colon cancer to immune therapy.  OncoImmunology 2018;7(11):e1498438.
  4. Li Q, Anderson CD, Egilmez NK.  Inhaled IL-10 suppresses lung tumorigenesis via abrogation of inflammatory macrophage-Th17 cell sxis.  Journal of Immunology2018;201(9):2842-2850.
  5. Li Q, Egilmez NK.  Ontogeny of tumor-associated CD4+CD25+Foxp3+ T-regulatory cells.  Immunological Investigations. 2016;19:1-17.
  6. Li Q, Virtuoso LP, Anderson CD, Egilmez NK.  Regulatory rebound in IL-12-treated tumors is driven by uncommitted peripheral regulatory T cells.  Journal of Immunology. 2015;195(3):1293-1300.
  7. Ozbilge H, LeVea C, Chung AY, Li Q, Egilmez NK.  Modulating gut immunity and neoplasia with oral cytokine adjuvants.  Oncoimmunology 2015;4(4):e1002724.
  8. Chung AY, Li Q, Blair SJ, De Jesus M, Dennis KL, LeVea C, Yao J, Sun Y, Conway TF, Virtuoso LP, Battaglia NG, Furtado S, Mathiowitz E, Mantis NJ, Khazaie K, Egilmez NK.  Oral interleukin-10 alleviates polyposis via neutralization of pathogenic T-regulatory cells.  Cancer Research 2014;74(19):5377-5385.
  9. Huntoon KM, Russell L, Tracy E, Barbour KW, Li Q, Shrikant PA, Berger FG, Garrett-Sinha LA, Baumann H.  A unique form of haptoglobin produced by murine hematopoietic cells supports B-cell survival, differentiation and immune response.  Molecular Immunology. 2013;55(3-4):345-354.
  10. Li Q, Rao RR, Vazzana J, Goedegebuure P, Gillanders W, OdunsiK, Shrikant PA.Regulating mammalian target of rapamycin to tune vaccination-induced CD8+ T cell responses for tumor immunity.  Journal of Immunology 2012;188(7):3080-3087.
  11. Li Q, Rao RR, Araki K, Pollizzi K, Odunsi K, Powell JD, Shrikant PA.  A central role for mTOR in Homeostatic Proliferation (HP) induced CD8+ T cell memory and tumor immunity.  Immunity 2001;34(4):541-553.
  12. Li Q, Eppolito C, Odunsi K, Shrikant PA.  Antigen-induced Erk1/2 activation regulates Ets-1-mediated sensitization of CD8+ T cells for IL-12 responses  Journal of Leukocyte Biology 2010;87: 257-263
  13. Li Q, Cheryl E, Odunsi K, Shrikant PA.  IL-12 programmed long-term CD8+ T cell responses require STAT4.  Journal of Immunology 2006;177:7618-7625
  14. Li Q, Pan P-Y, Gu P, Xu D, Chen S-H.  The role of immature myeloid Gr-1+ cells in the development of anti-tumor immunity.  Cancer Research 2004;64:1130-1139.
  15. Li Q, Harden JL, Anderson CD, Egilmez NK.  Tolerogenic phenotype of IFN-γ-induced IDO+ dendritic cells is maintained via an autocrine IDO-kynurenine/AhR-IDO loop.  Journal of Immunology 2016;197(3):962-970